<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089267</url>
  </required_header>
  <id_info>
    <org_study_id>3sbio-TPO-403</org_study_id>
    <nct_id>NCT04089267</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Sunshine Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a review of the efficacy and safety of different recombinant human thrombopoietin
      (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluating the efficacy and safety of different human thrombopoietin (rhTPO) regimens in the
      treatment of patients with primary immune thrombocytopenia (ITP) This trial was designed as a
      multicenter, randomized, open, parallel controlled study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Platelet count from baseline on day 14 after the first dose</measure>
    <time_frame>for day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total effective rate of ITP patients on day 14 (V6, D14 ± 1) after the first dose.</measure>
    <time_frame>for day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Platelet count from baseline on day 7 and day28 after the first dose</measure>
    <time_frame>for day7and day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the total effective rate of treatment in ITP patients on day 7 and day 28</measure>
    <time_frame>for day7and day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>up to 28days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-rhTPO antibodies</measure>
    <time_frame>up to 28days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav</measure>
    <time_frame>up to 28days</time_frame>
    <description>average Blood concentration at steady state Blood concentration at steady state Blood concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss</measure>
    <time_frame>up to 28days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>ITP</condition>
  <arm_group>
    <arm_group_label>experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO injection7500 U ;one time a day; 14 times of administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO injection15000 U;one time a day;14 times of administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO injection15000 U;1 time every other day, 7 times;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO injection30000 U；1 time every other day, 7 times;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPO</intervention_name>
    <arm_group_label>experimental group 1</arm_group_label>
    <arm_group_label>experimental group 2</arm_group_label>
    <arm_group_label>experimental group 3</arm_group_label>
    <arm_group_label>experimental group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old, male or female

          -  For patients who have been diagnosed with ITP, the diagnostic criteria are consistent
             with the Chinese Expert Consensus on Diagnosis and Treatment of Primary Immune
             Thrombocytopenia (2016 Edition)

          -  Recurrence after previous treatment with glucocorticoids is ineffective or effective

          -  No contraindications to rhTPO (Terbyus) application, and willing to accept rhTPO
             treatment

          -  Platelet count before enrollment ≤ 30 × 109 / L, or &gt; 30 × 109 / L but with active
             bleeding

          -  Volunteer to participate in the study and sign the informed consent form

        Exclusion Criteria:

          -  pregnant or lactating

          -  Those with a history of thrombosis

          -  severe cardiopulmonary liver and kidney dysfunction: creatinine level ≥ 176.8μmol / l
             (2mg / dl), transaminase, bilirubin levels higher than the upper limit of the normal
             value of 3 times

          -  Those who have used rhTPO in the past 2 weeks, or who have undergone splenectomy
             within 2 months, or who have been treated with danazol for less than 1 month, or have
             recently applied the following ITP treatments but have not yet reached the efficacy
             judgment time. : C-ball (7 days), vincristine or vinblastine amide or rhIL-11 (2
             weeks), Eltrombopag (1 month), or rituximab (2 months)

          -  In the case of previous treatment of rhTPO: rhTPO 300U/kg/d, 14 days of treatment is
             invalid;

          -  Severe or uncontrollable infections

          -  have a history of mental illness

          -  The investigator believes that the patient is not eligible to participate in any other
             circumstances of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Second People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510317</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Panyu Central Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>511400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Institute of Hematology and Oncology</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan University of Science and Technology First Affiliated Hospital</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Central Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>renmin Hospital of Wuhan University Hubei General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loudi Central Hospital</name>
      <address>
        <city>Loudi</city>
        <state>Hunan</state>
        <zip>417118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi An Central Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710499</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Blood Disease Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region Chinese Medicine Hospital,</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lishui City Center Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Xinjiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinxiang Central Hospital,</name>
      <address>
        <city>Xinxiang</city>
        <zip>453699</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

